Protocol of the STRIDE-X study: a multicenter, single-arm trial of single tremelimumab regular interval durvalumab followed by hepatectomy for initially unresectable hepatocellular carcinoma
Authors:
- Hajime MatsushimaHMHajime Matsushima
- Akihiko SoyamaASAkihiko Soyama
- Tomoaki YohTYTomoaki Yoh
- Takamichi IshiiTITakamichi Ishii
- Mei NakamuraMNMei Nakamura
- Fuyuki InagakiFIFuyuki Inagaki
- Fumika KamehamaFKFumika Kamehama
- Yasuharu SasakiYSYasuharu Sasaki
- Kohei UemuraKUKohei Uemura
- Etsuro HatanoEHEtsuro Hatano
- Kiyoshi HasegawaKHKiyoshi Hasegawa
Open Access
- 24 August 2026
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
Abstract
Background: Hepatocellular carcinoma (HCC) ranks as the fifth most common cancer globally and the third leading cause of cancer-related deaths. Systemic therapies such as lenvatinib or the combination of atezolizumab and bevacizumab have recently emerged as first-line therapies for advanced HCC. The introduction of tremelimumab with durvalumab (STRIDE regimen) has shown potential in improving overall survival (OS) in unresectable cases, making these patients candidates for surgical intervention post-treatment. Methods: The STRIDE-X study is a prospective, multicenter, single-arm trial aimed at evaluating the efficacy of single-dose tremelimumab combined with durvalumab, followed by hepatectomy, in patients with initially unresectable HCC. This non-randomized, open-label study will enroll subjects based on specific inclusion criteria. Eligible patients will undergo initial intravenous doses of tremelimumab and durvalumab, followed by an assessment of resectability via imaging at 8 and 16 weeks. If tumors become resectable, surgery will be scheduled 3–8 weeks after the last treatment dose. The primary endpoint is the incidence of postoperative complications of Clavien–Dindo grade III or higher following hepatectomy performed after STRIDE therapy. Secondary endpoints include resection rate, on-protocol resection rate, curative resection rate, post-hepatectomy liver failure, progression-free survival (PFS), OS, overall response rate, and ICG retention rate following STRIDE therapy. Safety and quality of life during the treatment course will also be assessed. Exploratory endpoints include analyses of plasma PD-L1, PD-1, CTLA-4, cytokines, circulating tumor DNA, and the immunological evaluation of resected surgical specimens. Discussion: This study aims to elucidate the safety of conversion surgery with the STRIDE regimen for initially unresectable HCC. In addition, efficacy (PFS and OS), the conversion rate during the treatment course, and analyses of relevant biomarkers will also be assessed.Keywords
All Related Versions
This publication has 12 references indexed in Scilit:
- Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCCJournal of Hepatology, 2025
- Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaAnnals of Oncology, 2024
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaNEJM Evidence, 2022
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunityNature Cancer, 2021
- Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody CombinationsLiver Cancer, 2021
- Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 updateHepatology Research, 2019
- Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases?: A systematic reviewEuropean Journal of Surgical Oncology, 2017
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Classification of Surgical ComplicationsAnnals of Surgery, 2004